20816-79-9

Usage

Uses

Used in Organic Synthesis:
1-Bromo-8-chloronaphthalene is used as a reagent in the preparation of peri-substituted naphthalene series. The presence of bromine and chlorine atoms at the 1 and 8 positions, respectively, allows for selective functionalization and substitution reactions, enabling the synthesis of a wide range of naphthalene-based compounds with diverse applications in various industries.
Used in Pharmaceutical Industry:
1-Bromo-8-chloronaphthalene can be used as a building block for the synthesis of pharmaceutical compounds. The halogenated naphthalene core can be further modified to incorporate various functional groups, leading to the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
1-Bromo-8-chloronaphthalene serves as a valuable research tool in the field of organic chemistry. Its unique structure and reactivity make it an ideal candidate for studying various chemical reactions and mechanisms, contributing to the advancement of chemical knowledge and the development of new synthetic methodologies.
Used in Dye and Pigment Industry:
1-Bromo-8-chloronaphthalene can be employed as a precursor for the synthesis of dyes and pigments. The halogenated naphthalene structure can be further functionalized to produce a variety of colored compounds, which can be used in the production of inks, paints, and other coloring materials.

Upstream product

• 7647-01-0 hydrogenchloride 
• 145-74-4 8-chloronaphthalene-1-sulfonic acid 
• 7726-95-6 bromine 
• 479-27-6 naphthalene-1,8-diamine 
• 204-03-5 1H-naphtho[1,8-de][1,2,3]triazine 
• 59107-51-6 8-chloronaphthalen-1-amine 

Relevant academic research and scientific papers

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

COVALENT RAS INHIBITORS AND USES THEREOF

The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.

KRAS G12C INHIBITORS

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

PROCESS FOR SYNTHESIS OF AROMATIC COMPOUNDS

The present invention refers to a process for preparing a compound of the formula (I) wherein R denotes an organic radical which, together with the two carbon atoms to which it is bonded, forms a carbocyclic or heterocyclic ring; R1, R2, R3 and X, independently, denote hydrogen, halogen, nitro, cyano or an organic radical; or R1 and R2 or R2 and R3, together with the carbon atoms to which they are bonded, form a ring; which comprises exposing a compound of the formula (II) wherein R1, R2, R3 and X are defined as given above and Y and Z, independently, have one of the meanings of X; to an energy source in the presence of a catalyst system.

Process for the preparation of chloroarylacetylene precursors

Chloroarylacetylenes such as m-chlorophenylacetylene and certain precursors to such chloroarylacetylene are prepared by reacting a chloroarylbromide with a substituted terminal acetylene compound containing at least three carbon atoms and a hydroxy group on the carbon atom adjacent to the acetylene group in the presence of a dialkyl or trialkyl amine solvent and a catalyst system consisting of a palladium complex containing two halogen moieties and two tri-substituted phosphine moieties. Additional triphenylphosphine can be added. A cuprous iodide promoter is also employed in the reaction sequence.